Vertex Pharmaceuticals Inc
- 取引所
- 米国株
- 国 / 地域
- USA
- 上場日
- 1991年7月24日
- 従業員数
- 6,400
- 公式サイト
- www.vrtx.com
総合バリュエーションレンジ · 保守的 $170–$240 / 妥当 $280–$360 / 楽観的 $430–$500。$479 時点で 楽観的な本源的価値レンジ内 · 多くの期待を織り込み済み。
レポート公開時 $434.52（2026年5月23日）
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
沿革
Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. The company completed its IPO on July 24, 1991. In 2024 it acquired Alpine for an equity value of about USD 4.9 billion (about USD 4.6 billion on a net-cash basis), adding povetacicept to its pipeline. In 2025 Vertex discontinued its VX-264 program after efficacy did not support further advancement, recording an intangible asset impairment of about USD 379 million.
業界での地位
Vertex is a global biotechnology company in the Healthcare sector, operating in the United States, Europe, and internationally, with about 6,400 employees. Its commercialized therapeutic areas include cystic fibrosis (CF), sickle cell disease, transfusion-dependent beta thalassemia, and acute pain, with marketed products including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, CASGEVY, and JOURNAVX. In 2025 total revenue was about USD 12.0 billion and research and development expense was about USD 3.9 billion. Named industry peers include Regeneron, Gilead, Biogen, and Amgen.
この銘柄のレポートはお使いの言語でまだありません。